san diego venture group; venture summit 2013; presnell
Post on 19-Oct-2014
404 views
DESCRIPTION
Organovo's Sharon Presnell, Ph.D., presents "Shaping the Future of Medicine…from better drugs to tissue on-demand"TRANSCRIPT
![Page 1: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/1.jpg)
Shaping the Future of Medicine… from be6er drugs to 8ssue on-‐demand
Sharon Presnell, Ph.D. Chief Technology Officer
© Copyright 2013, Organovo Holdings, Inc. This report is solely for the use of intended audience. No part of it may be circulated, quoted, or reproduced for distribution outside the organization without prior written
approval from Organovo Holdings, Inc.
![Page 2: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/2.jpg)
SAFE HARBOR STATEMENT
2
NYSEMKT: ONVO
©Copyright 2013 Organovo, Inc.
Any statements contained in this presentaAon that do not describe historical facts may consAtute forward-‐looking statements as that term is defined in the Private SecuriAes LiAgaAon Reform Act of 1995. Any forward-‐looking statements contained herein are based on current expectaAons, but are subject to a number of risks and uncertainAes. The factors that could cause actual future results to differ materially from current expectaAons include, but are not limited to, risks and uncertainAes relaAng to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substanAal addiAonal funding for the Company to conAnue its operaAons and to conduct research and development, clinical studies and future product commercializaAon; and, the Company's business, research, product development, regulatory approval, markeAng and distribuAon plans and strategies. These and other factors are idenAfied and described in more detail in our filings with the SEC, including our annual report for the period ended December 31, 2012 on Form 10-‐K and our current reports filed on Form 8K. We do not undertake to update these forward-‐looking statements made by us.
![Page 3: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/3.jpg)
3
![Page 4: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/4.jpg)
4
KIDNEY DONORS Data Sources: • USRDS • UNOS
KIDNEY TRANSPLANT WAITLIST
![Page 5: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/5.jpg)
5
KIDNEY DONORS Data Sources: • USRDS • UNOS
KIDNEY TRANSPLANT WAITLIST
PEOPLE WITH END-‐STAGE RENAL FAILURE
PEOPLE WITH MID-‐ TO LATE-‐STAGE CKD
![Page 6: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/6.jpg)
Target Discovery Lead ID Lead Op<miza<on ADMET Development Registra<on
and approval
6
Living human cells are widely used in drug development and regenerative medicine
©Copyright 2013 Organovo, Inc.
CELL-‐BASED ASSAYS CELLS & TISSUES AS THERAPEUTIC AGENTS
From Zreiqat et al., Biomaterials 2010 31:3175
![Page 7: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/7.jpg)
7
(NYSEMKT: ONVO)
• Founded in 2007, based on proprietary bio-‐prinAng technology developed at the University of Missouri with a $5M NaAonal Science FoundaAon grant
• Based in San Diego in a 15,000 sq i facility with dedicated bioprinAng / Assue culture and analyAcal laboratories
• A leader in “3D prinAng” of human Assue targeAng in
vitro and in vivo applicaAons
2012
©Copyright 2013 Organovo, Inc.
![Page 8: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/8.jpg)
8
![Page 9: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/9.jpg)
Peripheral Nerve
Lung
Bone
Blood Vessel
Skeletal Muscle
Liver
Cardiac
©Copyright 2013 Organovo, Inc.
![Page 10: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/10.jpg)
Organovo’s 3D Human Liver Tissue Array
Standard Corning TranswellTM Plates
• Automated, reproducible • Represents naAve human Assue
10 ©Copyright 2013 Organovo, Inc.
NATIVE LIVER TISSUE ONVO 3D LIVER TISSUE LIVER CELLS ON 3D SCAFFOLD
From Mat Sci Eng 2012 C32:310
![Page 11: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/11.jpg)
Organovo’s 3D Human Liver Tissue Array • Automated, reproducible • Represents naAve human Assue • Exhibits superior funcAon
11 ©Copyright 2013 Organovo, Inc.
ONVO Standard 3D 2D
LIVE
R-‐SPEC
IFIC PRO
TEIN SEC
RETION
(ng Albu
min / mL / m
illion cells)
* p < 0.001
![Page 12: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/12.jpg)
Enabling blood supply… A critical step in building implantable tissues
From establishing microvascular networks… …to simple blood vessels
…to branched vascular trees Vascular Networks (brown) in
bioprinted human Assue
Bioprinted Branched Vessel
![Page 13: San Diego Venture Group; Venture Summit 2013; Presnell](https://reader033.vdocuments.mx/reader033/viewer/2022051608/54446958b1af9f600a8b48e2/html5/thumbnails/13.jpg)
13 ©Copyright 2013 Organovo, Inc.
Partner Companies & Institutions